Istradefylline
- Generic Name
- Istradefylline
- Brand Names
- Nourianz
- Drug Type
- Small Molecule
- Chemical Formula
- C20H24N4O4
- CAS Number
- 155270-99-8
- Unique Ingredient Identifier
- 2GZ0LIK7T4
- Background
Istradefylline, or KW6002, was developed by Kyowa Hakko Kirin in Japan for the treatment of Parkinson's disease as an adjunct to standard therapy. Unlike standard dopaminergic therapies for Parkinson's, Istradefylline targets adenosine A receptors in the basal ganglia. This region of the brain is highly involved in motor control.
...
- Indication
Istradefylline is indicated in adjunct to levodopa and carbidopa in the treatment of Parkinson's disease.
- Associated Conditions
- Parkinson's Disease (PD)
- Associated Therapies
- -
Combining Low Oxygen Therapy and an Adenosine A2a Receptor Antagonist to Improve Functional Mobility After Spinal Cord Injury
- Conditions
- Interventions
- First Posted Date
- 2022-02-01
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- Randy Trumbower, PT, PhD
- Target Recruit Count
- 40
- Registration Number
- NCT05217498
- Locations
- 🇺🇸
Spaulding Rehabilitation Hospital, Cambridge, Massachusetts, United States
A Study to Evaluate Abuse Potential of Istradefylline
- Conditions
- Interventions
- First Posted Date
- 2015-11-20
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Kyowa Kirin Co., Ltd.
- Target Recruit Count
- 42
- Registration Number
- NCT02609477
- Locations
- 🇺🇸
Pharmaceutical Research Associates, Inc, Salt Lake City, Utah, United States
Effect of Mild Hepatic Impairment on the Pharmacokinetics of Istradefylline
- First Posted Date
- 2014-10-03
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Kyowa Kirin Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT02256033
- Locations
- 🇺🇸
Noccr/Vrg, Knoxville, Tennessee, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
Long-Term Safety Study of KW-6002 (Istradefylline) in Parkinson's Disease Patients
- First Posted Date
- 2009-08-12
- Last Posted Date
- 2012-08-31
- Lead Sponsor
- Kyowa Kirin Co., Ltd.
- Target Recruit Count
- 308
- Registration Number
- NCT00957203
Study of KW-6002 (Istradefylline) for the Treatment of Parkinson's Disease in Patients Taking Levodopa
- First Posted Date
- 2009-08-10
- Last Posted Date
- 2012-08-29
- Lead Sponsor
- Kyowa Kirin Co., Ltd.
- Target Recruit Count
- 373
- Registration Number
- NCT00955526
A Long-Term, Safety Study With a Flexible Dose Range of KW-6002 in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy
- First Posted Date
- 2009-08-07
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Kyowa Kirin, Inc.
- Registration Number
- NCT00955045
- Locations
- 🇺🇸
48 Centers in the US and 4 in Canada, Princeton, New Jersey, United States
A Phase 2b Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa
- First Posted Date
- 2007-04-03
- Last Posted Date
- 2012-08-29
- Lead Sponsor
- Kyowa Kirin Co., Ltd.
- Target Recruit Count
- 363
- Registration Number
- NCT00455507
Study of KW-6002 (Istradefylline) in Parkinson's Disease in Patients With Motor Response Complications on Levodopa
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2013-06-11
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 10
- Registration Number
- NCT00203957
- Locations
- 🇺🇸
The University of Chicago, Chicago, Illinois, United States
An Extension of Istradefylline in North American Parkinson's Disease Patients Who Have Completed Study 6002-INT-001
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Kyowa Kirin, Inc.
- Target Recruit Count
- 504
- Registration Number
- NCT00199381
- Locations
- 🇺🇸
Kyowa Pharmaceutical Inc., Princeton, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.